Symfo International SA has been officially accepted into Technoport®, CRP Henri Tudor’s high-tech business incubator.
Symfo International SA develops data collection tools for pharmaceutical companies and research institutes carrying out clinical trials on new medical devices or drugs. Symfo’s technology solutions combine total traceability and ease of use, and comply with guidances and regulations of the US Food and Drug Administration and European EMEA, as well as those of major emerging countries like China.
Already used by pharmaceutical companies like Astra Zeneca and Mead Johnson, as well as biotechnology companies and US universities, Symfo’s solutions enable the drug industry to significantly reduce new product development costs while optimizing the quality of clinical trials. Mobile technologies developed by Symfo enable data collected by patients participating to the trials to be managed efficiently and automatically regardless of their geographical location, and allow precise and auditable clinical data to be collected quickly and easily.
Symfo’s founders are specialists from the medical and technological world and have earned excellent references in the US market. Supported by Eurefi and CD-PME, the company intends to step up its development in the international market and become a recognized partner in clinical trials management. Technoport® welcomes this new arrival, which takes the number of hosted companies to 14, added to the 14 companies that have successfully left the incubator since the end of 2000.